- Poster presentation
- Open Access
Comparative evaluation of the anti-Hepatitis B virus activity of Centella asiatica and Camellia sinensis (green tea)
© Thanigaivel et al; licensee BioMed Central Ltd. 2014
- Published: 27 May 2014
Chronic Hepatitis B virus (HBV) infection is a major health problem and available anti-HBV drugs are known to cause side effects in addition to increased incidence of drug resistance. In the current study anti-HBV properties of Centella asiatica and Camellia sinensis was evaluated.
For the assay, equal volume of HBV virus was mixed with extract of C. asiatica or C. sinensis and incubated at 37°C for 5 days. The supernatant was assayed for the presence of bound/unbound HBsAg using ELISA. A dose response analysis was done for each extract and cytotoxicity of the each extract was measured by MTT assay.
Dose response anti HBV revealed that methanolic extract C. asiatica indicated that 2.5 mg/mL concentrations was inhibitory to 0.75 pg/mL of HBV. Aqueous and methanolic extract of C. sinensis indicated that 0.5 mg/mL and 0.25 concentrations inhibited HBV, respectively. Interestingly, EGCG indicated 1.5 pg/mL HBV was inhibited by 25µg/mL. These concentrations were well tolerated by HepG2 cells and the non toxic concentration was up to 800 µg/mL.
The study showed that EGCG outperformed other extracts and had anti-HBV activity with minimal concentration (25 µg/mL). This is followed by extracts of C. sisensis which exhibited medium anti HBV activity. Poorest anti-HBV activity was noticed with C. asiatica i.e.2.5 mg. None of the extracts had cytotoxicity. From this study we could conclude that C. sinensis extracts are better in inhibiting HBV.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.